Expertise in
4
conditions

Dr. Thomas R. Klumpp

Hematology Oncology
925 Chestnut St, Suite 320a, 
Philadelphia, PA 
40 Years of Experience
Expertise in
4
conditions
925 Chestnut St, Suite 320a, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Thomas Klumpp is a Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Klumpp has been practicing medicine for over 40 years is highly rated in 4 conditions, according to our data. His top areas of expertise are Graft Versus Host Disease (GvHD), Chromosome 6 Uniparental Disomy, Febrile Neutropenia, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 25 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in PA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

925 Chestnut St, Suite 320a, Philadelphia, PA 19107

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Post Transplant Cyclophosphamide for Unrelated and Related Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Post Transplant Cyclophosphamide for Unrelated and Related Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Enrollment Status: Completed
Publish Date: December 15, 2025
Intervention Type: Drug, Radiation, Genetic
Study Phase: Phase 2
A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy
A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy
Enrollment Status: Completed
Publish Date: December 10, 2025
Intervention Type: Drug
Study Drugs: Sirolimus, Azacitidine
Study Phase: Phase 2
A Two-Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Cutaneous T Cell Lymphoma
A Two-Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Cutaneous T Cell Lymphoma
Enrollment Status: Withdrawn
Publish Date: May 02, 2025
Intervention Type: Drug, Radiation, Biological, Procedure
Study Phase: Phase 1
A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia
A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: April 29, 2025
Intervention Type: Drug
Study Phase: Early Phase 1
A Two Step Approach to Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
A Two Step Approach to Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: April 24, 2025
Intervention Type: Drug, Radiation, Other, Biological, Procedure
Study Drugs: Fludarabine, T Cell-Depleted Donor Lymphocyte Infusion, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil
Study Phase: Phase 2
A Biomarker Validation Study to Establish Whether Serial Flow Cytometric Measurements Predict Clinical Response to Sirolimus and MEC (Mitoxantrone Etoposide Cytarabine) Treatment in Patients With High-Risk Acute Myelogenous Leukemia
A Biomarker Validation Study to Establish Whether Serial Flow Cytometric Measurements Predict Clinical Response to Sirolimus and MEC (Mitoxantrone Etoposide Cytarabine) Treatment in Patients With High-Risk Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Drug
Study Drugs: Sirolimus, Mitoxantrone, Etoposide, Cytarabine
Study Phase: Phase 2
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: November 17, 2022
Intervention Type: Radiation, Drug, Biological, Device, Procedure
Study Drugs: Fludarabine, Busulfan, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Donor Lymphocyte Infusion
Study Phase: Phase 2
View 6 Less Clinical Trials

25 Total Publications

A prospective study of posttransplant cyclophosphamide for unrelated donor peripheral blood stem cell transplant with special attention to graft content and the impact of a higher γδ T cell dose.
A prospective study of posttransplant cyclophosphamide for unrelated donor peripheral blood stem cell transplant with special attention to graft content and the impact of a higher γδ T cell dose.
Journal: European journal of haematology
Published: October 15, 2023
Similar Doctors
Expertise in
25
conditions
Dr. Pierluigi Porcu
Hematology Oncology | Oncology | Hematology
Expertise in
25
conditions
Dr. Pierluigi Porcu
Hematology Oncology | Oncology | Hematology

Jefferson University Physicians

925 Chestnut St, Suite 3, 
Philadelphia, PA 
 (0.1 miles away)
215-955-8874
Languages Spoken:
English
See accepted insurances

Pierluigi Porcu is a Hematologist Oncology specialist and an Oncologist in Philadelphia, Pennsylvania. Dr. Porcu is highly rated in 25 conditions, according to our data. His top areas of expertise are T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
11
conditions
Dr. Anita J. Kumar
Hematology Oncology
Expertise in
11
conditions
Dr. Anita J. Kumar
Hematology Oncology
3400 Spruce Street, 16 Penn Tower, 
Philadelphia, PA 
 (2.0 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances

Anita Kumar is a Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Kumar is highly rated in 11 conditions, according to our data. Her top areas of expertise are Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
27
conditions
Dr. Arthur P. Staddon
Hematology Oncology
Expertise in
27
conditions
Dr. Arthur P. Staddon
Hematology Oncology
230 W Washington Sq, 2nd Floor, 
Philadelphia, PA 
 (0.3 miles away)
215-829-6088
Languages Spoken:
English
See accepted insurances

Arthur Staddon is a Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Staddon is highly rated in 27 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Rhabdomyosarcoma, Alveolar Soft Part Sarcoma, and Synovial Sarcoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Klumpp's expertise for a condition
ConditionClose
      View All 30 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile